Skip Navigation Links
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Overall Recruitment Status: Active, currently enrolling
 
Official Title
Randomized Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
 
Region Sponsors
California - Northern
Ancora Heart, Inc.
 
Acronym KP IRB No.
1710470
 
Study Type Phase
Clinical Trial n/a
 
Study Population Description
(Adult, Older Adult) Male and Female with Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
 
Purpose
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
 
Detailed Description
The CORCINCH-HF Study is a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation of the AccuCinch Ventricular Restoration System. Subjects will be randomized in a 1:1 ratio: 1. Treatment group: AccuCinch Ventricular Restoration System plus guideline-directed medical therapy (GDMT) (n~200) 2. Control group: Guideline-directed medical therapy (GDMT) (n~200)
 
Gender Age Limit
Male & Female 18 years & older
 
Inclusion Criteria
  • Age 18-years or older
  • Ejection Fraction: >20% and <40% measured by transthoracic echocardiography (TTE) and assessed by an echocardiography (echo) core lab
  • LV end-diastolic diameter >55 mm measured by TTE and assessed by an echo core lab
  • Symptom Status: * NYHA III, * NYHA ambulatory IV, or * NYHA II with a heart failure hospitalization within the prior 12 months (of signing the consent)
  • Able to complete six-minute walk test with distance between 100 m and 450 m
  • Please contact study team for additional inclusion criteria
 
Exclusion Criteria
  • Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 90 days prior to consent
  • Untreated clinically significant coronary artery disease (CAD) requiring revascularization
  • Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation
  • Suboptimal ventricular anatomy or wall thickness as determined from screening echocardiography and/or CT scan
  • Heart failure on the basis other than ischemic or non-ischemic dilated cardiomyopathy (e.g., hypertrophic cardiomyopathy, amyloid cardiomyopathy, restrictive cardiomyopathy, uncorrected congenital heart disease, constrictive pericarditis)
  • Hemodynamic instability within 30 days prior to the implant defined as subject requiring inotropic support or mechanical hemodynamic support
  • Please contact study team for additional exclusion criteria

 
Keywords and/or Specific Medical Conditions
  • 5019
  • Genetic Diseases, Inborn
  • Cardiomegaly
  • Heart Diseases
  • Cardiomyopathies
  • Heart Failure
  • Cardiomyopathy, Dilated
  • Laminopathies
  • Cardiovascular Diseases
  • Cardiology
 
KP Clinical Facility
  • San Francisco Medical Center
 
Clinical Area
  • Cardiology


Principal Investigator:
Van N Selby, MD
Contact Information:
- Cardiology KPNC
-San Francisco Medical Center


smilelady1
Do you want to receive
Email Alerts?

Sign Up Here!





Regional Research Sites: